ClinicalTrials.gg
CompletedNCT06009094Updated Dec 10, 2024

Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis

A Phase 1 interventional study of VC005 and VC005 Placebo in Atopic Dermatitis, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-10.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
139th of 190
80 · median 164
Started
2023
with 38 others
Phase 1
38 of 206
14 open now
Registered
83rd of 206
by date
Lead sponsor
9 of 206
Jiangsu vcare pharmaceutical technology co., LTD

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 139th largest by enrollment of the 190 interventional ones that give a count, is one of 39 that started in 2023, is one of 38 in phase 1, and was the 83rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This study is a single center, randomized, double-blind, Vehicle controlled,, single and multiple dose clinical study.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

healthy subject's study:

  1. Healthy male or female subjects, aged 18-45 years (including critical values);
  2. (BMI) between 18 and 26kg/m2 (including critical values), with male weight ≥ 50kg and female weight ≥ 45kg;
  3. All women and men with fertility potential must be willing to use at least one efficient method of from the signing of the form until 3 months after the last administration of the study drug, as detailed in Appendix 5;
  4. Voluntarily participate in the experiment and sign an informed consent form;
  5. Subjects who are able to communicate well with the researcher and are willing and able to comply with all planned visits, treatment plans, laboratory tests, and other research procedures

patient's study:

  1. When informed consent is given, the age range is between 18 and 75 years (including the boundary value), regardless of gender;
  2. Body mass index (BMI) between 18 and 26kg/m2 (including critical values), with male weight ≥ 50kg and female weight ≥ 45kg;
  3. Before administration, the diagnosis of mild to moderate atopic dermatitis should be met:

    Overall Investigator Assessment (IGA) score of 2 to 3 points; Atopic dermatitis: total area of skin lesions 3% ≤ body surface area≤ 20%

  4. Voluntarily sign an informed consent form (with a date), indicating that the subject has been informed of all relevant parts of the study;
  5. All women and men with the possibility of childbirth must be willing to use at least one efficient method of contraception from the signing of the informed consent form until 3 months after the last administration of the study drug, as detailed in Appendix 5;
  6. Subjects who are willing and able to comply with planned visits and treatment plans, laboratory tests, and other research procedures

Exclusion criteria

Exclusion Criteria:

healthy subject's study:

  1. Suspected of being allergic to the study drug or any component of the study drug, or having an allergic constitution;
  2. Those who have received the vaccine within 2 weeks before administration or plan to receive the vaccine during the study period;
  3. Screening for individuals who have undergone any surgery within the previous 6 months;
  4. Those who participated in blood donation within the first 3 months of screening and had a blood donation volume of ≥ 400 mL, or received blood transfusion (excluding female physiological blood loss);
  5. Female subjects of childbearing age had unprotected sexual intercourse with their opposite sex partner within 14 days prior to screening;
  6. Screening of clinical trial participants (including groups) who have participated in any drug or medical device within the first 3 months;
  7. Pregnant and lactating women;
  8. Patients with difficulty in blood collection or inability to tolerate venous puncture, and those with a history of needle and blood fainting;
  9. Those who smoke ≥ 5 cigarettes per day within the first 3 months of screening, and cannot stop using any tobacco products from the end of screening to enrollment and during the trial period;
  10. Those who have consumed more than 14 units of alcohol per week (1 unit of alcohol ≈ 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) within the first 3 months of screening, or who cannot abstain from alcohol during the trial period;
  11. Other situations where the researcher determines that it is not suitable to participate in the experiment.

patient's study:

  1. Suspected of being allergic to the study drug or any component of the study drug, or having an allergic constitution;
  2. Those who have received the vaccine within 2 weeks before administration or plan to receive the vaccine during the study period;
  3. Screening for individuals who have undergone any surgery within the previous 6 months;
  4. Those who participated in blood donation within the first 3 months of screening and had a blood donation volume of ≥ 400 mL, or received blood transfusion (excluding female physiological blood loss);
  5. Screening of clinical trial participants (including excipient groups) who have participated in any drug or medical device within the first 3 months;
  6. Pregnant and lactating women;
  7. Patients with difficulty in blood collection or inability to tolerate venous puncture, and those with a history of needle and blood fainting;
  8. Those who smoke ≥ 5 cigarettes per day within the first 3 months of screening, and cannot stop using any tobacco products from the end of screening to enrollment and during the trial period;
  9. Those who have consumed more than 14 units of alcohol per week (1 unit of alcohol ≈ 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) within the first 3 months of screening, or who cannot abstain from alcohol during the trial period;
  10. Other situations where the researcher determines that it is not suitable to participate in the experiment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    VC005 Low Dose groups

    Drug: VC005

  • Experimental
    VC005 median-A Dose groups

    Drug: VC005

  • Experimental
    VC005 median-B Dose groups

    Drug: VC005

  • Experimental
    VC005 high Dose groups

    Drug: VC005

  • Placebo comparator
    VC005 Placebo groups

    Drug: VC005 Placebo

Interventions

  • DrugVC005

    VC005 group with Local topical application

  • DrugVC005 Placebo

    VC005 Placebo group with Local topical application

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Time frame: Day2,Day 4,Day17,Day31

Secondary outcomes

  1. Changes in EASI(Eczema area and severity index) from baseline

    Time frame: Week 2,Week 4

07

Study locations

1 site
  • Chinese Academy of Medical Sciences Hospital of Skin Disease
    Nanjing, Jiangsu, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in May 2024, 9 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 9 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2023
First posted
Aug 24, 2023
StartActual
Jul 27, 2023
Primary completionActual
May 23, 2024
CompletionActual
May 23, 2024
Last update
Dec 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06009094
Responsible party
Sponsor
First posted
Aug 24, 2023
Start date
Jul 27, 2023
Primary completion
May 23, 2024
Completion
May 23, 2024
Last update
Dec 10, 2024

Study contacts

Qianjin Lu
principal investigator · Chinese Academy of Medical Sciences Hospital of Skin Disease

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VC005

Start the discussion